Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy-Reference-Cited by-同舟云学术

Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy

Published:2020-02-06 Issue:6 Volume:189 Page:1119-1126
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Smith Stephen D.¹²^ORCID,Till Brian G.²,Shadman Mazyar S.²,Lynch Ryan C.¹²,Cowan Andrew J.¹²,Wu Qian V.²,Voutsinas Jenna²,Rasmussen Heather A.¹,Blue Katherine¹,Ujjani Chaitra S.¹²^ORCID,Shustov Andrei²³,Cassaday Ryan D.²³,Fromm Jonathan R.⁴,Gopal Ajay K.¹²

Affiliation:

1. Division of Medical Oncology Department of Internal Medicine University of Washington Seattle WA USA

2. Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA

3. Division of Hematology Department of Internal Medicine University of Washington Seattle WA USA

4. Division of Hematopathology Department of Laboratory Medicine University of Washington Seattle WA USA

Funder

Merck Sharp and Dohme

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16494

Reference39 articles.

1. Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells

2. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

3. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

4. Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration

5. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy of targeting CD20 antibody and immune checkpoint inhibitor may be a breakthrough in the treatment of B-cell lymphoma;Heliyon;2024-07

2. Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas;Cancers;2024-06-17

3. Predicting central nervous system relapse in primary breast diffuse large B-cell lymphoma using the stage-modified IPI score: A retrospective cohort study;Heliyon;2024-03

4. Case report: From sequence to solution: tailoring treatment for transformed follicular lymphoma (DLBCL) through next generation sequencing study;Frontiers in Oncology;2024-02-29

5. Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up;Clinical Lymphoma Myeloma and Leukemia;2024-02